Clinical Trial Update: Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

View source ↗

Summary

A clinical trial update reports reduced oligodendrocyte-specific cytotoxicity observed with Ofatumumab treatment in Relapsing Remitting Multiple Sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: University of Southern California | Conditions: Relapsing Remitting Multiple Sclerosis | Status: ACTIVE_NOT_RECRUITING